This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

28 Nov 2011

Immunicum Cancer Vaccine Receives Approval for Clinical Trial

A clinical phase I/II trial will be initiated within the next few months on 12 patients with metastatic renal cancer.

Swedish cancer vaccine company Immunicum has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala.


At the same time, the company has secured the largest capital injection in the company's history through a successful new share issue to enable it to complete the clinical trial.


"It's a big and important step to test the vaccine on humans for the first time," said Jamal El-Mosleh, ceo of Immunicum. "Our animal studies have shown good results, so we feel safe to continue."


Immunicum's vaccine is based on using dendritic cells from he

Related News